Core Viewpoint - Oriental Bio has experienced a stock price increase of 5.11% on November 12, reaching 28.57 CNY per share, with a total market capitalization of 5.76 billion CNY, indicating a cumulative increase of 4.34% over three consecutive days [1] Company Overview - Zhejiang Oriental Gene Biological Products Co., Ltd. was established on December 1, 2005, and went public on February 5, 2020. The company specializes in the research, production, and sales of in vitro diagnostic products, with 97.99% of its revenue coming from diagnostic reagents and 2.01% from other supplementary sources [1] Shareholder Analysis - The top circulating shareholder of Oriental Bio includes a fund from Rongtong Fund, which reduced its holdings by 1.7 million shares in the third quarter, now holding 2.8 million shares, representing 1.39% of the circulating shares. The fund has gained approximately 3.89 million CNY in floating profit today and 3.16 million CNY during the three-day increase [2] Fund Performance - The Rongtong Health Industry Flexible Allocation Mixed A/B Fund (000727) has a total scale of 1.816 billion CNY and has achieved a year-to-date return of 15.36%, ranking 5146 out of 8147 in its category. Over the past year, it has returned 1.86%, ranking 7321 out of 8056, and since inception, it has returned 178.7% [2] Fund Holdings - The Rongtong Health Industry Flexible Allocation Mixed A/B Fund (000727) has Oriental Bio as its tenth largest holding, with 2.98% of the fund's net value allocated to this stock. The fund manager, Wan Minyuan, has been in position for 9 years and 81 days, with the best return during his tenure being 143.42% and the worst being -21.5% [3]

Summary of Key Points Core Viewpoint The Beijing Stock Exchange (BSE) has seen a decrease in trading volume and value over the past week, with a total of 282 listed companies as of November 9, 2025. The market is also witnessing new listings and ongoing IPO activities, indicating a dynamic but challenging environment for investors. Trading Activity - As of November 9, 2025, the BSE has 282 listed companies with a total share capital of 39.225 billion shares and a circulating share capital of 25.056 billion shares [2] - For the week of November 3 to November 9, the trading volume was 4.925 billion shares, a decrease of 17.24% week-on-week, while the trading value was 1136.16 billion yuan, down 21.40% from the previous week [3] - The average trading price during this period was 23.07 yuan, reflecting a decrease of 5.03% [3] - The BSE 50 Index fell by 3.79% to 1522.73 points, with 9 stocks rising and 41 stocks declining [3] New Listings and IPOs - Two companies successfully listed on the BSE during the week of November 3 to November 9, 2025 [7] - The newly listed companies include: - **Danna (Tianjin) Biotechnology Co., Ltd.**: Listed on November 3, 2025, with a first-day trading surge of 497.08% and a closing price of 102.10 yuan [8][10] - **Zhongcheng Consulting Group Co., Ltd.**: Listed on November 7, 2025, with a first-day increase of 170.08% and a closing price of 35.60 yuan [13][30] - Both companies aim to raise approximately 1.37 billion yuan for various projects, including R&D and infrastructure [10][30] Financial Performance of Newly Listed Companies - **Danna Biotechnology**: - Revenue for 2022-2024: 295 million yuan, 237 million yuan, 240 million yuan; Net profit: 44.62 million yuan, 77.60 million yuan, 87.19 million yuan [10] - 2025 H1 revenue decreased by 1.38% to 116 million yuan, while net profit increased by 29.55% to 49.96 million yuan [11] - **Zhongcheng Consulting**: - Revenue for 2022-2024: 303 million yuan, 368 million yuan, 396 million yuan; Net profit: 64.36 million yuan, 81.06 million yuan, 105 million yuan [13] - 2025 H1 revenue decreased by 4.08% to 191 million yuan, and net profit decreased by 2.66% to 53.29 million yuan [14] Ongoing IPO Activities - As of November 9, 2025, there are 104 companies awaiting approval for listing on the BSE, with various stages of the IPO process [6] - Two companies submitted registration during the week, while three companies passed the listing committee meetings [25][26] - Notable companies that passed the listing committee include: - **Qilong Ocean**: Engaged in oil drilling equipment manufacturing, aiming to raise 382 million yuan [27] - **Haiseng Medical**: Focused on medical device manufacturing, seeking to raise 370 million yuan [30] - **Guoliang New Materials**: Specializing in refractory materials, aiming to raise 175 million yuan [33] Market Dynamics - The BSE is experiencing fluctuations in trading activity and new listings, reflecting both opportunities and challenges in the current market environment [3][6][25]

Core Viewpoint - The stock of Beijing Hotgen Biotech Co., Ltd. increased by 5.32% on November 10, reaching a price of 143.50 yuan per share, with a trading volume of 276 million yuan and a turnover rate of 2.11%, resulting in a total market capitalization of 13.304 billion yuan [1]. Company Overview - Beijing Hotgen Biotech Co., Ltd. was established on June 23, 2005, and went public on September 30, 2019. The company is located in the Daxing District of Beijing and specializes in the research, development, production, and sales of in vitro diagnostic reagents and instruments [1]. - The revenue composition of the company includes: 70.87% from testing reagents, 19.79% from testing instruments, 8.17% from other sources, and 1.17% from biological raw materials [1]. Fund Holdings - According to data, one fund under Huaxia Fund has a significant holding in Hotgen Biotech. The Huaxia SSE STAR 200 ETF (588820) increased its holdings by 28,000 shares in the third quarter, bringing the total to 29,600 shares, which accounts for 1.06% of the fund's net value, making it the tenth largest holding [2]. - The Huaxia SSE STAR 200 ETF (588820) was established on December 23, 2024, with a latest scale of 476 million yuan. Year-to-date, it has achieved a return of 53.55%, ranking 500 out of 4217 in its category, and a cumulative return of 52.86% since inception [2]. Fund Manager Information - The fund manager of the Huaxia SSE STAR 200 ETF (588820) is Hualong. As of the report date, Hualong has been in the position for 3 years and 82 days, managing total assets of 35.957 billion yuan. The best fund return during this period was 107.73%, while the worst was -15.08% [3].

Group 1 - The North Exchange 50 index decreased by 3.79%, but trading volume remained above 20 billion, showing an increase from the previous 17 billion [8][19] - The market adjustment was a natural pullback after a previous policy-driven surge, with a focus on sectors like electricity, chemicals, photovoltaics, lithium batteries, and energy storage, which performed well [8][9] - The themes of anti-involution and price increases are spreading, aligning with market demands for "high cuts and low" [9][10] Group 2 - The North Exchange's PE (TTM) average is 89.33 times, with a median of 44.73 times, indicating a decrease in valuation [22][30] - The trading volume for the week was 4.922 billion shares, a decrease of 17.23% from the previous week, while the trading amount was 113.591 billion yuan, down 21.37% [26][19] - The margin financing balance increased to 7.951 billion yuan, up by 0.47 billion yuan from the previous week [28][19] Group 3 - Two new stocks were listed this week: Danna Biological and Zhongcheng Consulting, with significant first-day price increases of 497.08% and 170.08% respectively [32][33] - As of November 7, 2025, there are 282 companies listed on the North Exchange [32] - Next week, one company (Nante Technology) is scheduled for subscription, and two companies (Tongbao Optoelectronics, Agricultural University Technology) are set for review [37] Group 4 - Among the North Exchange stocks, 52 increased while 229 decreased, resulting in a rise-fall ratio of 0.23 [40] - The top gainers included Caneng Electric (+31.13%) and Anda Technology (+20.38%) [41][40] - The top five stocks by turnover rate were Caneng Electric, Jinhua New Materials, and Deer Chemical, indicating high trading activity [46]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The flu virus is a highly pathogenic pathogen, emphasizing the importance of flu prevention and treatment [14] - The flu activity is on the rise, with northern regions reporting the highest number of cases in nearly four years [16] - The strategic significance of flu prevention and treatment is highlighted, with opportunities expected in the vaccine, diagnostic, and antiviral drug sectors [19] Summary by Sections Flu Virus and Its Impact - Influenza is a common respiratory infectious disease with a high transmission rate and seasonal patterns, affecting approximately 1 billion people globally each year, with 300,000 to 500,000 severe cases and 290,000 to 650,000 deaths related to respiratory diseases caused by influenza [15] - The flu activity has shown an upward trend, with the ILI% reported at 5.1% in northern provinces, exceeding levels from previous years [16] Market Performance - In the first week of November 2025, the pharmaceutical and biological sector declined by 2.4%, underperforming the CSI 300 index by 3.22 percentage points, ranking 29th among 31 sub-industries [6][26] - The pharmaceutical circulation sector saw the highest increase, up by 1.59%, while the medical research outsourcing sector experienced the largest decline, down by 4.93% [26] Investment Opportunities - The flu prevention and treatment strategy is gaining importance, with structural opportunities expected in the vaccine, diagnostic, and antiviral drug industries due to low vaccination rates and ongoing virus mutations [19] - Specific companies benefiting from the flu season include Innotest and Ansun Biologics in the in vitro diagnostics sector, Huazhong Biological in the biological products sector, and Zhongsheng Pharmaceutical in the traditional Chinese medicine sector [5] Recommended Stocks - Monthly stock recommendations include: Sanofi, Innovent Biologics, Baillie Gifford, Frontier Biologics, Haofan Biologics, Aopumai, Shanghai Yizhong, WuXi Biologics, Zai Lab, and Fangsheng Pharmaceutical [7] - Weekly stock recommendations include: Yaokang Biologics, Bidu Pharmaceuticals, Haoyuan Pharmaceuticals, China Resources Sanjiu, Huadong Medicine, Sunshine Nuohuo, Yuekang Pharmaceuticals, Zhongsheng Pharmaceuticals, and Jichuan Pharmaceuticals [7]

Core Viewpoint - Innotech's stock price has shown fluctuations, with a year-to-date decline of 8.23% but a recent recovery in the last five trading days, indicating potential market interest and volatility [2]. Company Overview - Innotech Biotechnology Co., Ltd. is located in Fengtai District, Beijing, and was established on February 6, 2006. The company went public on July 28, 2022, and specializes in the research, production, and sales of POCT rapid diagnostic products [2]. - The main revenue composition includes respiratory series (96.49%), other reagent series (2.99%), and preconception series (0.51%) [2]. - The company is classified under the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics [2]. Financial Performance - For the period from January to September 2025, Innotech reported a revenue of 330 million yuan, representing a year-on-year decrease of 36.56%. The net profit attributable to the parent company was 131 million yuan, down 46.37% year-on-year [2]. - As of September 30, 2025, the total number of shareholders was 8,037, an increase of 10.57% from the previous period, while the average circulating shares per person decreased by 8.86% to 8,627 shares [2]. Stock Performance and Trading Activity - On November 7, Innotech's stock price increased by 2.15%, reaching 32.77 yuan per share, with a trading volume of 22.37 million yuan and a turnover rate of 1.00%. The total market capitalization stood at 4.489 billion yuan [1]. - The net inflow of main funds was 467,300 yuan, with significant selling activity amounting to 1.666 million yuan, indicating mixed investor sentiment [1]. Dividend Information - Since its A-share listing, Innotech has distributed a total of 152 million yuan in dividends [3]. Institutional Holdings - As of September 30, 2025, the medical device ETF (159883) was the ninth largest circulating shareholder, holding 498,000 shares as a new shareholder [3].

Group 1 - The sixth Panoramic Investor Relations Gold Award was recently announced, with Jiukang Biological (300406.SZ) winning the "Outstanding IR Team" award and its Secretary Wang Jianmin receiving the "Outstanding Secretary" award [1] - The evaluation process involved self-nomination, public online voting, professional index scoring, and expert review, covering thousands of A-share companies, establishing itself as a benchmark in the capital market IR field [1] - The award focuses on six innovative dimensions: digital investor relations, response to small investors' concerns, institutional attention, market value management, shareholder returns, and ESG value dissemination, marking Jiukang Biological's IR management as recognized by the capital market [1] Group 2 - Jiukang Biological has been a leader in the domestic in vitro diagnostic industry for 20 years, developing a diversified and high-quality diagnostic testing platform [2] - The company has established various biochemical research and development platforms, including chemical methods, enzyme methods, and immunoassay techniques, and has high-level R&D capabilities in liquid blood coagulation and blood type testing [2] - Jiukang Biological's subsidiary, Maxin Biological, focuses on core technologies in pathological diagnosis and explores innovative technologies such as companion diagnostics and AI in pathology, aiming for the integrated development of six technical platforms [2]

Group 1 - The core point of the article is the leadership changes at Mingde Biological, with Chen Lili elected as the new chairperson and general manager, and Wang Ying appointed as the vice chairperson and vice general manager [1][7] - Chen Lili has a strong academic background, holding a doctorate from Heidelberg University and postdoctoral experience at Boston University Medical Center [2][4] - The company was founded in 2008 by Chen Lili and Wang Ying, and it successfully went public on the Shenzhen Stock Exchange in 2018 [4][8] Group 2 - As of the third quarter of 2025, Mingde Biological reported a revenue of 227 million yuan, a year-on-year increase of 0.53%, while the net profit attributable to shareholders decreased by 83.30% to 13.52 million yuan [8] - The company's stock closed at 18.78 yuan per share on November 5, with a market capitalization of approximately 4.367 billion yuan [10]

Group 1 - The core point of the article is that Anbiping (SH 688393) announced a share reduction plan by its major shareholders, which may impact the stock price and market perception of the company [1] - As of the announcement date, shareholders including Zhuhai Gaotejia Ruian Investment Partnership and others hold approximately 6.73% of Anbiping's total shares, amounting to about 6.29 million shares [1] - The shareholders plan to reduce their holdings by up to approximately 940,000 shares, which is not more than 1% of the company's total share capital, within three months starting 15 trading days after the announcement [1] Group 2 - Anbiping's revenue composition for the year 2024 is projected to be 98.73% from in vitro diagnostics and 1.27% from other businesses [1] - The current market capitalization of Anbiping is reported to be 2.4 billion yuan [2]

Group 1 - The core point of the news is that Selys Medical has seen a stock price increase of 5.89%, reaching 26.24 CNY per share, with a total market capitalization of 5.515 billion CNY [1] - Selys Medical, established on February 23, 2004, and listed on October 31, 2016, is primarily engaged in medical testing, marketing services, and the development, production, and sales of in vitro diagnostic products [1] - The revenue composition of Selys Medical includes 39.91% from IVD business, 38.01% from SPD business, and 22.08% from pure sales [1] Group 2 - According to data, one fund under Caitong Securities Asset Management holds a significant position in Selys Medical, with 200,000 shares, representing 5.72% of the fund's net value, ranking as the tenth largest holding [2] - Caitong Asset Management Healthcare Mixed A Fund (018484) has achieved a year-to-date return of 26.65% and a one-year return of 24.44%, ranking 3236 out of 8150 and 3250 out of 8043 respectively [2] - The fund was established on August 3, 2023, with a current scale of 64.3006 million CNY, and has generated an estimated floating profit of approximately 292,000 CNY today [2]